Werewolf Therapeutics
HOWL
61 hedge funds and large institutions have $209M invested in Werewolf Therapeutics in 2024 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 15 increasing their positions, 12 reducing their positions, and 4 closing their positions.
525% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 4
96% more capital invested
Capital invested by funds: $107M → $209M (+$102M)
49% more funds holding
Funds holding: 41 → 61 (+20)
25% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 12
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less ownership
Funds ownership: 76.46% → 75.46% (-1%)
86% less call options, than puts
Call options by funds: $32K | Put options by funds: $227K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$9.84M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$5.19M |
| 3 |
EHI
Eagle Health Investments
Greenwich,
Connecticut
|
+$4.08M |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
+$3.33M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$2.69M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$1.83M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1.25M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.17M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$196K |
HOWL Hedge Fund Activity: Q1 2024 in Review
61 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Werewolf Therapeutics (HOWL) for Q1 2024, worth a combined $209M — up 96% from $107M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new HOWL positions and 4 closed out — a net gain of 21 holders — while 15 added to existing stakes and 12 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $9.84M. The largest seller was PFM Health Sciences, cutting an estimated $2.69M.
- 61 institutional investors held Werewolf Therapeutics (HOWL) as of Q1 2024, up from 41 in Q4 2023.
- Funds reported $209M of Werewolf Therapeutics stock for Q1 2024, up 96% quarter-over-quarter.
- 25 funds opened new Werewolf Therapeutics positions in Q1 2024 and 4 closed out, a net change of +21 holders.
- The largest Werewolf Therapeutics buyer in Q1 2024 was Janus Henderson Group, an estimated $9.84M added.
- The largest Werewolf Therapeutics seller in Q1 2024 was PFM Health Sciences, an estimated $2.69M sold.
Based on aggregated 13F filings for Q1 2024.